There are currently 39 active clinical trials seeking participants for Neuroblastoma research studies. The states with the highest number of trials for Neuroblastoma participants are California, Texas, New York and Florida.
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Recruiting
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab bi... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
08/22/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +162 locations
Conditions: Neuroblastoma, Ganglioneuroblastoma, Nodular
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
Recruiting
Background: Neuroblastoma is a type of cancer that causes tumors in nerves. It affects mainly infants and toddlers, and it causes about 15 percent of cancer-related deaths in children. Objective: To test a new drug (rhIL-15), combined with 3 standard cancer drugs, in people with neuroblastoma. Eligibility: People aged 3 to 35 years with neuroblastoma that did not respond or returned after standard treatment. Design: Participants will be screened. They will have a physical exam with blood... Read More
Gender:
ALL
Ages:
Between 3 years and 35 years
Trial Updated:
08/20/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neuroblastoma
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Recruiting
The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.
Gender:
ALL
Ages:
All
Trial Updated:
08/19/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Recruiting
The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.
Gender:
ALL
Ages:
All
Trial Updated:
08/19/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey +6 locations
Conditions: Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
Phase II Study of Proton Radiation Therapy for Neuroblastoma
Recruiting
This research study is evaluating a therapy called proton beam radiation therapy (PBRT) as a possible treatment for neuroblastoma. Neuroblastoma most commonly occurs in and around the adrenal glands, which are located at the top of the kidneys. However, it can also occur in other areas where groups of nerve cells exist, such as other areas of the abdomen, neck and near the spine. Conventional radiation therapy with photons is used as standard treatment for many patients with neuroblastic tumor... Read More
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
08/18/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Neuroblastoma, Ganglioneuroblastoma
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Recruiting
Background: * Endocrine neoplasms (tumors) are among the fastest growing tumors in incidence in the United States. Furthermore, it is often difficult to distinguish between benign or malignant tumors in cancers of the thyroid, parathyroid, adrenal gland, and pancreas. More research is needed to improve detection and treatment options for patients who develop these kinds of cancer. * Researchers are interested in studying the molecular changes that are involved in endocrine cancer development an... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Endocrine Tumors, Thyroid Neoplasms, Parathyroid Neoplasms, Adrenal Neoplasm, Neuroblastoma
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
Recruiting
Background: - Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childhood cancers such as leukemia and tumors of the central nervous system. Objectives: - To collect and st... Read More
Gender:
ALL
Ages:
4 weeks and above
Trial Updated:
08/13/2025
Locations: Children's National Medical Center, Washington, District of Columbia +4 locations
Conditions: Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, Renal Cancer
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Recruiting
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2
Gender:
ALL
Ages:
1 year and above
Trial Updated:
08/12/2025
Locations: University of Florida, Gainesville, Florida +25 locations
Conditions: Neuroblastoma
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Recruiting
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have been shown to either express known targets of cabozantinib or with preclinical evidence of efficacy, including specifically neuroblastomas. These tumors have high morbidity and mortality, particularly... Read More
Gender:
ALL
Ages:
Between 18 months and 40 years
Trial Updated:
08/08/2025
Locations: Children's Hospital of Alabama/UAB, Birmingham, Alabama +5 locations
Conditions: Neuroblastoma, Sarcoma
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Recruiting
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.
Gender:
ALL
Ages:
Between 12 months and 30 years
Trial Updated:
08/08/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +20 locations
Conditions: Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Recruiting
The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
08/04/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma, Pheochromocytoma
Rapid Administration Pilot for Infusing Dinutuximab
Recruiting
Studies have shown that the anti-GD2 human-mouse chimeric monoclonal antibody dinutuximab has contributed significantly to the improvement of treatment for children with high-risk neuroblastoma and has become a mainstay in treating high risk neuroblastoma in children as part of up-front therapy and relapsed/refractory therapy. The administration of dinutuximab requires a significant amount of time and resources to complete the 10-20 hour standard infusion time for 4 days in the inpatient setting... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
08/04/2025
Locations: Childrens Hospital Los Angeles, Los Angeles, California
Conditions: Neuroblastoma